دورية أكاديمية
أعرض في EDS

The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.

التفاصيل البيبلوغرافية
العنوان: The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.
المؤلفون: de la Court JR; Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Department of Medical Microbiology and Infection Prevention, University of Amsterdam, Amsterdam, The Netherlands., Bruns AHW; Department of Infectious Diseases, University Medical Centre Utrecht, University of Utrecht, Utrecht, The Netherlands., Roukens AHE; Department of Infectious Diseases, Leiden University Centre of Infectious Diseases, Leiden University Medical Centre, Leiden University, Leiden, The Netherlands., Baas IO; Department of Medical Oncology, University Medical Centre Utrecht, University of Utrecht, Utrecht, The Netherlands., van Steeg K; Department of Clinical Pharmacology, ZGT Hospital, University of Groningen, Almelo and Hengelo, The Netherlands., Toren-Wielema ML; Department of Clinical Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Tersmette M; Department of Medical Microbiology and Immunology, Sint Antonius Hospital, Nieuwegein and Utrecht, The Netherlands., Blijlevens NMA; Department of Haematology, Radboud University Medical Centre, Radboud University, Nijmegen, The Netherlands., Huis In 't Veld RAG; Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Wolfs TFW; Division of Paediatric Immunology and Infectious Diseases, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands., Tissing WJE; Department of Pediatric Oncology and Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Department of Pediatric Oncology and Hematology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Kyuchukova Y; Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Heijmans J; Department of Haematology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. j.heijmans@amsterdamumc.nl.
المصدر: Infectious diseases and therapy [Infect Dis Ther] 2022 Dec; Vol. 11 (6), pp. 2063-2098. Date of Electronic Publication: 2022 Oct 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2014- : [Auckland] Adis
Original Publication: [London] : Springer Healthcare
مستخلص: Introduction: This guideline was written by a multidisciplinary committee with mandated members of the Dutch Society for Infectious Diseases, Dutch Society for Hematology, Dutch Society for Medical Oncology, Dutch Association of Hospital Pharmacists, Dutch Society for Medical Microbiology, and Dutch Society for Pediatrics. The guideline is written for adults and pediatric patients.
Method: The recommendations are based on the answers to nine questions formulated by the guideline committee. To provide evidence-based recommendations we used all relevant clinical guidelines published since 2010 as a source, supplemented with systematic searches and evaluation of the recent literature (2010-2020) and, where necessary, supplemented by expert-based advice.
Results: For adults the guideline distinguishes between high- and standard-risk neutropenia based on expected duration of neutropenia (> 7 days versus ≤ 7 days). Where possible a distinction has been made between pediatric and adult patients.
Conclusion: This guideline was written to aid diagnosis and management of patients with febrile neutropenia due to chemotherapy in the Netherlands. The guideline provides recommendation for children and adults. Adults patient are subdivided as having a standard- or high-risk neutropenic episode based on estimated duration of neutropenia. The most important recommendations are as follows. In adults with high-risk neutropenia (duration of neutropenia > 7 days) and in children with neutropenia, ceftazidime, cefepime, and piperacillin-tazobactam are all first-choice options for empirical antibiotic therapy in case of fever. In adults with standard-risk neutropenia (duration of neutropenia ≤ 7 days) the MASCC score can be used to assess the individual risk of infectious complications. For patients with a low risk of infectious complications (high MASCC score) oral antibiotic therapy in an outpatient setting is recommended. For patients with a high risk of infectious complications (low MASCC score) antibiotic therapy per protocol sepsis of unknown origin is recommended.
(© 2022. The Author(s).)
References: Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66. (PMID: 1657591910.1002/cncr.21847)
Zuckermann J, Moreira LB, Stoll P, et al. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol. 2008;87(2):139–45. (PMID: 1793892610.1007/s00277-007-0390-7)
de la Court JR, de Jonge NA, Bomers M, et al. Empirische antibiotische therapie voor koorts bij neutropenie in Nederland. Ned Tijdschr Med Microbiol. 2018;26(3).
de la Court JR, Bruns AHW, Roukens AHE, et al. Recommendations for the diagnosis and management of febrile neutropenia in patients with cancer. 2022. https://swab.nl/nl/febriele-neutropenie-algemene-informatie .
Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839-842. (PMID: 20603348300153010.1503/cmaj.090449)
SWAB. Format richtlijnontwikkeling. https://www.swab.nl . Updated 29 September 2017. https://www.swab.nl/swab/cms3.nsf/viewdoc/A4D8293A248F3EFFC12581AD00319A53 . Accessed 2 Jan 2020.
Blijlevens NMA, Janssen JJWM, Meis JFG, et al. SWAB Guidelines for the Management of Invasive Fungal Infections. 2017. https://swab.nl/exec/file/download/86 . Accessed 5 Dec 2019.
Castellini G, Bruschettini M, Gianola S, et al. Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and trial sequential analysis. Syst Rev. 2018;7(1):110. (PMID: 30055658606462110.1186/s13643-018-0770-1)
Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003;1(1):23–35. (PMID: 1862812810.3816/SCT.2003.n.002)
Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–37. (PMID: 1471675510.1002/cncr.11882)
Heinz WJ, Buchheidt D, Christopeit M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017;96(11):1775–92. (PMID: 28856437564542810.1007/s00277-017-3098-3)
Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–40. (PMID: 521629410.7326/0003-4819-64-2-328)
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–93. (PMID: 2125809410.1093/cid/cir073)
Carmona-Bayonas A, Jimenez-Fonseca P, de Castro EM, et al. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clin Transl Oncol. 2019;21(1):75–86. (PMID: 3047099110.1007/s12094-018-1983-4)
Liu CY, Lai YC, Huang LJ, et al. Impact of bloodstream infections on outcome and the influence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2011;46(9):1231–9. (PMID: 2111318610.1038/bmt.2010.286)
Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018;320(10):995–1004. (PMID: 30208456614309810.1001/jama.2018.12512)
Chong Y, Yakushiji H, Ito Y, et al. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis. 2011;15(4):e277–281. (PMID: 2132472310.1016/j.ijid.2010.12.010)
Garnica M, Nouér SA, Pellegrino FLPC, et al. Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis. 2013;13(1):356. (PMID: 23899356372982310.1186/1471-2334-13-356)
Sohn BS, Yoon DH, Kim S, et al. The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience. Eur J Clin Microbiol Infect Dis. 2012;31(7):1653–61. (PMID: 2213880510.1007/s10096-011-1489-2)
Vehreschild JJ, Moritz G, Vehreschild MJGT, et al. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. Int J Antimicrob Agents. 2012;39(2):130–4. (PMID: 2216940810.1016/j.ijantimicag.2011.10.009)
Wolska A, Robak T, Szmigielska-Kaplon A, et al. Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT)—a single-center experience. Adv Med Sci. 2012;57(1):118–23. (PMID: 2236626510.2478/v10039-012-0004-z)
Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer. 1999;85(1):213–9. (PMID: 992199510.1002/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.0.CO;2-D)
Innes HE, Smith DB, O’Reilly SM, et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer. 2003;89(1):43–9. (PMID: 12838298239422010.1038/sj.bjc.6600993)
Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy–EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31(9):1149–56. (PMID: 2335898310.1200/JCO.2012.45.8109)
Malik IA, Khan WA, Karim M, et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med. 1995;98(3):224–31. (PMID: 787233710.1016/S0002-9343(99)80367-2)
Minotti V, Gentile G, Bucaneve G, et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer. 1999;7(3):134–9. (PMID: 1033593110.1007/s005200050243)
Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76(1):20–37. (PMID: 2907932310.1016/j.jinf.2017.10.009)
Verlinden A, Jansens H, Goossens H, et al. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Eur J Haematol. 2014;93(4):302–8. (PMID: 2475035010.1111/ejh.12345)
Rivas‐Ruiz R, Villasis‐Keever M, Miranda‐Novales G, et al. Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event. Cochrane Database of Syst Rev. 2019;2019(3).
Paul M, Dickstein Y, Borok S, et al. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2014;1:CD003914.
Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000;160(4):501–9. (PMID: 1069569010.1001/archinte.160.4.501)
Kang C-I, Kim S-H, Kim H-B, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37(6):745–51. (PMID: 1295563310.1086/377200)
Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;2010(11):C005197.
Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7(5):338–48. (PMID: 1744893710.1016/S1473-3099(07)70109-3)
Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010;51(4):381–9. (PMID: 2062406510.1086/655131)
FDA. Information for healthcare professionals: Cefepime (marketed as Maxipime). 2009.
Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328(7441):668. (PMID: 1499669938121810.1136/bmj.38028.520995.63)
Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013;2013(6):CD003038. (PMID: 6457814)
Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2002;2(4):231–42. (PMID: 1193742310.1016/S1473-3099(02)00241-4)
Robinson PD, Lehrnbecher T, Phillips R, et al. Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review of randomized trials. J Clin Oncol. 2016;34(17):2054–60. (PMID: 2702211410.1200/JCO.2015.65.8591)
Sieswerda E, Bax HI, Hoogerwerf JJ, et al. The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults. BMC Infect Dis. 2022;22:687. https://doi.org/10.1186/s12879-022-07653-3 . (PMID: 35953772937354310.1186/s12879-022-07653-3)
Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38(5):931–6. (PMID: 806777218812910.1128/AAC.38.5.931)
Cojutti PG, Candoni A, Lazzarotto D, et al. Population pharmacokinetics of continuous-infusion meropenem in febrile neutropenic patients with hematologic malignancies: dosing strategies for optimizing empirical treatment against enterobacterales and P. aeruginosa. Pharmaceutics. 2020;12(9):785. (PMID: 756022510.3390/pharmaceutics12090785)
Álvarez JC, Cuervo SI, Silva E, et al. Pharmacokinetics and pharmacodynamics of cefepime in adults with hematological malignancies and febrile neutropenia after chemotherapy. Antibiotics (Basel). 2021;10(5):504. (PMID: 10.3390/antibiotics10050504)
Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother. 2005;49(8):3550–3. (PMID: 16048982119622710.1128/AAC.49.8.3550-3553.2005)
Rhodes NJ, Grove ME, Kiel PJ, et al. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. Int J Antimicrob Agents. 2017;50(3):482–6. (PMID: 2866869410.1016/j.ijantimicag.2017.04.008)
Sime FB, Hahn U, Warner MS, et al. Using population pharmacokinetic modeling and monte carlo simulations to determine whether standard doses of piperacillin in piperacillin–tazobactam regimens are adequate for the management of febrile neutropenia. Antimicrob Agents Chemother. 2017;61(11).
Fehér C, Rovira M, Soriano A, et al. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother. 2014;69(9):2556–62. (PMID: 2485512510.1093/jac/dku150)
Ram R, Halavy Y, Amit O, et al. Extended vs bolus infusion of broad-spectrum β-lactams for febrile neutropenia: an unblended, randomized trial. Clin Infect Dis. 2018;67(8):1153–60. (PMID: 2960868010.1093/cid/ciy258)
Wrenn RH, Cluck D, Kennedy L, et al. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia. J Oncol Pharm Pract. 2018;24(3):170–5. (PMID: 2807704710.1177/1078155216687151)
Laporte-Amargos J, Gudiol C, Arnan M, et al. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). Trials. 2020;21(1):412. (PMID: 32423462723610310.1186/s13063-020-04323-0)
Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12):1826–35. (PMID: 24323983385695710.3324/haematol.2013.091025)
Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66(3):657–63. (PMID: 2119347510.1093/jac/dkq494)
Ben-Ami R, Olshtain-Pops K, Krieger M, et al. Antibiotic exposure as a risk factor for fluconazole-resistant candida bloodstream infection. Antimicrob Agents Chemother. 2012;56(5):2518–23. (PMID: 22314534334666810.1128/AAC.05947-11)
Satlin MJ, Cohen N, Ma KC, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73(4):336–45. (PMID: 27404978502691010.1016/j.jinf.2016.07.002)
Ballo O, Kreisel E-M, Eladly F, et al. Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy. Ann Hematol. 2020;99(11):2547–53. (PMID: 32974837753615710.1007/s00277-020-04274-1)
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51. (PMID: 1094413910.1200/JCO.2000.18.16.3038)
Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10(2):316–22. (PMID: 173243210.1200/JCO.1992.10.2.316)
Carmona-Bayonas A, Gomez J, Gonzalez-Billalabeitia E, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105(5):612–7. (PMID: 21811253318892910.1038/bjc.2011.284)
Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol. 1996;14(3):919–24. (PMID: 862204010.1200/JCO.1996.14.3.919)
Alexander SW, Wade KC, Hibberd PL, et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002;24(1):38–42. (PMID: 1190273810.1097/00043426-200201000-00011)
Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006;28(10):665–70. (PMID: 1702382710.1097/01.mph.0000212996.94929.0b)
Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19(14):3415–21. (PMID: 1145489010.1200/JCO.2001.19.14.3415)
Ammann RA, Hirt A, Luthy AR, et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol. 2003;41(5):436–43. (PMID: 1451538210.1002/mpo.10320)
Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol. 2010;28(12):2008–14. (PMID: 2023168010.1200/JCO.2009.25.8988)
Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35(18):2082–94. (PMID: 2845961410.1200/JCO.2016.71.7017)
Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999;341(5):312–8. (PMID: 1042346510.1056/NEJM199907293410502)
Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341(5):305–11. (PMID: 1042346410.1056/NEJM199907293410501)
Rolston KV, Frisbee-Hume SE, Patel S, et al. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer. 2010;18(1):89–94. (PMID: 1938769510.1007/s00520-009-0634-2)
Grillon A, Schramm F, Kleinberg M, et al. Comparative activity of ciprofloxacin, levofloxacin and moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia assessed by minimum inhibitory concentrations and time-kill studies. PLoS ONE. 2016;11(6): e0156690. (PMID: 27257956489262610.1371/journal.pone.0156690)
Rolston KV, Frisbee-Hume S, LeBlanc B, et al. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis. 2003;47(2):441–9. (PMID: 1452252010.1016/S0732-8893(03)00115-9)
Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443–53. (PMID: 2946191610.1200/JCO.2017.77.6211)
de Greeff S, Schoffelen A, Verduin C. NethMap 2020: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlandsin 2019/MARAN 2020: Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2019. In: Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2020.
Karthaus M, Egerer G, Kulimann KH, et al. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis. 1998;17(7):501–4. (PMID: 976455310.1007/BF01691133)
Cornely OA, Bethe U, Seifert H, et al. A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin. Ann Hematol. 2002;81(1):37–43. (PMID: 1180763410.1007/s00277-001-0392-9)
Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011;26(2):220–52. (PMID: 21716917311085910.3904/kjim.2011.26.2.220)
Bate J, Gibson F, Johnson E, et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Arch Dis Child Educ Pract Ed. 2013;98(2):73–5. (PMID: 2349239810.1136/archdischild-2013-303634)
Kochanek M, Schalk E, von Bergwelt-Baildon M, et al. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2019;98(5):1051–69. (PMID: 30796468646965310.1007/s00277-019-03622-0)
Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005;5(7):431–9. (PMID: 1597852910.1016/S1473-3099(05)70164-X)
Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(Suppl 3):iii35-44. (PMID: 20876627)
Cardona Zorrilla AF, Herault LR, Casasbuenas A, et al. Systematic review of case reports concerning adults suffering from neutropenic enterocolitis. Clin Transl Oncol. 2006;8(1):31–8. (PMID: 1663243710.1007/s12094-006-0092-y)
Pugliese N, Salvatore P, Iula DV, et al. Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia. Cancer Med. 2017;6(7):1500–11. (PMID: 28556623550433610.1002/cam4.1063)
Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med. 1979;67(2):194–200. (PMID: 38033610.1016/0002-9343(79)90390-5)
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111–8. (PMID: 2766424710.1093/annonc/mdw325)
Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol Oncol. 2000;22(5):405–11. (PMID: 1103785010.1097/00043426-200009000-00004)
Cherif H, Björkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem–cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis. 2004;36(8):593–600. (PMID: 1537067110.1080/00365540410017590)
Slobbe L, Waal L, Jongman LR, et al. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study. Eur J Cancer. 2009;45(16):2810–7. (PMID: 1964799510.1016/j.ejca.2009.06.025)
Le Clech L, Talarmin JP, Couturier MA, et al. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study. Infect Dis (Lond). 2018;50:1–11.
Puerta-Alcalde P, Cardozo C, Suárez-Lledó M, et al. Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies. Clin Microbiol Infect. 2019;25(4):447–53. (PMID: 3009641710.1016/j.cmi.2018.07.026)
Jensen JU, Hein L, Lundgren B, et al. Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin–tazobactam, meropenem, and cefuroxime. Crit Care Med. 2015;43(3):594–602. (PMID: 2549397010.1097/CCM.0000000000000746)
Ortíz Ruiz G, Osorio J, Valderrama S, et al. Risk factors for candidemia in non-neutropenic critical patients in Colombia. Med Intensiva. 2016;40(3):139–44. (PMID: 2672510510.1016/j.medin.2015.08.001)
Cornejo-Juárez P, Suárez-Cuenca JA, Volkow-Fernández P, et al. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Support Care Cancer. 2016;24(1):253–9. (PMID: 2601461610.1007/s00520-015-2772-z)
Forcina A, Lorentino F, Marasco V, et al. Clinical impact of pretransplant multidrug-resistant gram-negative colonization in autologous and allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(7):1476–82. (PMID: 2950178010.1016/j.bbmt.2018.02.021)
Kömürcü B, Tükenmez Tigen E, Toptaş T, et al. Rectal colonization with multidrug-resistant gram-negative bacteria in patients with hematological malignancies: a prospective study. Expert Rev Hematol. 2020;13:1–5. (PMID: 10.1080/17474086.2020.1787145)
Liss BJ, Vehreschild JJ, Cornely OA, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40(6):613–9. (PMID: 2266514310.1007/s15010-012-0269-y)
Nesher L, Rolston KV, Shah DP, et al. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transplant Infect Dis. 2015;17(1):33–8. (PMID: 10.1111/tid.12323)
Satlin MJ, Chavda KD, Baker TM, et al. Colonization with levofloxacin-resistant extended-spectrum β-lactamase-producing enterobacteriaceae and risk of bacteremia in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2018;67(11):1720–8. (PMID: 297017666233682)
Vehreschild MJ, Hamprecht A, Peterson L, et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother. 2014;69(12):3387–92. (PMID: 2510349210.1093/jac/dku305)
Narimatsu H, Kami M, Miyakoshi S, et al. Value of pretransplant screening for colonization of Pseudomonas aeruginosa in reduced-intensity umbilical cord blood transplantation for adult patients. Ann Hematol. 2007;86(6):449–51. (PMID: 1725614310.1007/s00277-007-0260-3)
Nguyen AD, Heil EL, Patel NK, et al. A single-center evaluation of the risk for colonization or bacteremia with piperacillin–tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis. J Oncol Pharm Pract. 2016;22(2):303–7. (PMID: 2556751710.1177/1078155214567161)
Cattaneo C, Di Blasi R, Skert C, et al. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97(9):1717–26. (PMID: 2970586010.1007/s00277-018-3341-6)
Jaiswal SR, Bhakuni P, Bhagwati G, et al. Impact of preemptive granulocyte infusions during febrile neutropenia in patients colonized with carbapenem-resistant gram-negative bacteria undergoing haploidentical transplantation. Biol Blood Marrow Transplant. 2019;25(8):1621–8. (PMID: 3104808610.1016/j.bbmt.2019.04.023)
Ballo O, Tarazzit I, Stratmann J, et al. Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy. PLoS ONE. 2019;14(1): e0210991. (PMID: 30673776634392210.1371/journal.pone.0210991)
Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–81. (PMID: 2742807210.1002/ajh.24489)
Andria N, Henig O, Kotler O, et al. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. J Antimicrob Chemother. 2015;70(11):3146–53. (PMID: 2620931210.1093/jac/dkv218)
Vidal F, Mensa J, Almela M, et al. Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P aeruginosa. QJM. 2003;96(3):227–34. (PMID: 1261598710.1093/qjmed/hcg031)
Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16(11):1576–81. (PMID: 20685257367041210.1016/j.bbmt.2010.05.008)
Matar MJ, Safdar A, Rolston KVI. Relationship of colonization with vancomycin-resistant enterococci and risk of systemic infection in patients with cancer. Clin Infect Dis. 2006;42(10):1506–7. (PMID: 1661917610.1086/503675)
Tsiatis AC, Manes B, Calder C, et al. Incidence and clinical complications of vancomycin-resistant enterococcus in pediatric stem cell transplant patients. Bone Marrow Transplant. 2004;33(9):937–41. (PMID: 1503454010.1038/sj.bmt.1704462)
Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13(5):615–21. (PMID: 1744892210.1016/j.bbmt.2007.01.078)
Zirakzadeh A, Gastineau DA, Mandrekar JN, et al. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41(4):385–92. (PMID: 1808434110.1038/sj.bmt.1705912)
Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med. 1994;97(3):256–64. (PMID: 809217510.1016/0002-9343(94)90009-4)
Richard P, Felice MP, Daeschler T, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet. 1995;345(8965):1607–9. (PMID: 778353810.1016/S0140-6736(95)90117-5)
Murali S, Langston A. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies. Transplant Infect Dis. 2009;11(6):480–90. (PMID: 10.1111/j.1399-3062.2009.00441.x)
Bow EJ. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol. 2008;140(2):133–52. (PMID: 1817375210.1111/j.1365-2141.2007.06906.x)
Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445–56. (PMID: 2644473110.1056/NEJMra1315399)
Schwartz C, Henrickson KJ, Roghmann K, et al. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol. 1990;8(9):1591–7. (PMID: 220279210.1200/JCO.1990.8.9.1591)
Smith SR, Cheesbrough J, Spearing R, et al. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother. 1989;33(8):1193–7. (PMID: 252981417262310.1128/AAC.33.8.1193)
Lazarus HM, Lowder JN, Anderson JM, et al. A prospective randomized trial of central venous catheter removal versus intravenous amphotericin B in febrile neutropenic patients. JPEN J Parenter Enteral Nutr. 1984;8(5):501–5. (PMID: 654171410.1177/0148607184008005501)
Atkinson JB, Chamberlin K, Boody BA. A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis. J Pediatr Surg. 1998;33(5):714–6. (PMID: 960747510.1016/S0022-3468(98)90194-4)
La Quaglia MP, Caldwell C, Lucas A, et al. A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. J Pediatr Surg. 1994;29(6):742–5. (PMID: 807801010.1016/0022-3468(94)90359-X)
Manian FA. IDSA guidelines for the diagnosis and management of intravascular catheter-related bloodstream infection. Clin Infect Dis. 2009;49(11):1770–1 (author reply 1771–1772). (PMID: 1989156810.1086/648113)
Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45. (PMID: 1948971010.1086/599376)
Verduin K, Ammerlaan H, Blaauw G, et al. Richtlijn Staphylococcus aureus bacteriëmie. 2018. https://www.nvmm.nl/media/3123/clean-richtlijn-s-aureus-bacteriemie-24-mei-2019.pdf .
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62(4):e1–50. (PMID: 26679628472538510.1093/cid/civ933)
Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014;2014(10):CD003039. (PMID: 7141179)
Gerritsen MG, Willemink MJ, Pompe E, et al. Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography. PLoS ONE. 2017;12(2): e0172256. (PMID: 28235014532531010.1371/journal.pone.0172256)
Zaleska-Dorobisz U, Olchowy C, Łasecki M, et al. Low-dose computed tomography in assessment of pulmonary abnormalities in children with febrile neutropenia suffering from malignant diseases. Adv Clin Exp Med. 2017;26(4):695–701. (PMID: 2869143110.17219/acem/68292)
Yolin-Raley DS, Dagogo-Jack I, Niell HB, et al. The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT. J Natl Compr Cancer Netw. 2015;13(2):184–9. (PMID: 10.6004/jnccn.2015.0027)
Cox JA, DeMasi J, McCollom S, et al. The diagnostic utility of routine chest radiography in the evaluation of the initial fever in patients undergoing hematopoietic stem cell. Pediatr Blood Cancer. 2011;57(4):666–8. (PMID: 2182678110.1002/pbc.22911)
Phillips RS, Lehrnbecher T, Alexander S, et al. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS ONE. 2012;7(5): e38300. (PMID: 22693615336504210.1371/journal.pone.0038300)
Roberts SD, Wells GM, Gandhi NM, et al. Diagnostic value of routine chest radiography in febrile, neutropenic children for early detection of pneumonia and mould infections. Support Care Cancer. 2012;20(10):2589–94. (PMID: 2227830710.1007/s00520-011-1366-7)
Estacio O, Loh Z, Baker A, et al. Limited utility of routine chest X-ray in initial evaluation of neutropenic fever in patients with haematological diseases undergoing chemotherapy. Intern Med J. 2018;48(5):556–60. (PMID: 2922756510.1111/imj.13712)
Klaassen IL, de Haas V, van Wijk JA, et al. Pyuria is absent during urinary tract infections in neutropenic patients. Pediatr Blood Cancer. 2011;56(5):868–70. (PMID: 2094959710.1002/pbc.22799)
Sandoval C, Sinaki B, Weiss R, et al. Urinary tract infections in pediatric oncology patients with fever and neutropenia. Pediatr Hematol Oncol. 2012;29(1):68–72. (PMID: 2230401210.3109/08880018.2011.617809)
فهرسة مساهمة: Keywords: Clinical practice guideline; Hematology and febrile neutropenia; Oncology
تواريخ الأحداث: Date Created: 20221013 Latest Revision: 20230216
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9669256
DOI: 10.1007/s40121-022-00700-1
PMID: 36229765
قاعدة البيانات: MEDLINE
الوصف
تدمد:2193-8229
DOI:10.1007/s40121-022-00700-1